ClinicalTrials.gg
CompletedNCT00071487Updated Aug 7, 2013Results posted

Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)

A Phase 2 interventional study of Placebo and Belimumab 1 mg/kg in Lupus Erythematosus, Systemic, sponsored by Human Genome Sciences Inc.. Completed at 62 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-08-07.

Sponsored by Human Genome Sciences Inc. (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
449
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
8th of 36
449 · median 81
Started
2003
the only one that year
Phase 2
8 of 36
2 open now
Registered
1st of 36
by date
Lead sponsor
6 of 36
Human Genome Sciences Inc.

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 8th largest by enrollment, is the only one that started in 2003, is one of 8 in phase 2, and was the 1st registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with active SLE disease.

Read the detailed description

The purpose of this study is to evaluate the safety and efficacy of three different doses of belimumab (1 mg/kg, 4 mg/kg, and 10 mg/kg), administered in addition to standard therapy, compared to placebo plus standard therapy in patients with active SLE disease. Patients were randomly assigned, following stratification by the screening SELENA SLEDAI score (4 to 7 versus ≥ 8), to 1 of the 4 study arms (3 active arms and 1 placebo arm plus standard therapy for SLE). All patients were to be dosed on Days 0, 14, and 28, then every 28 days for the remainder of 52 weeks. Patients completing the 52-week period could enter a 24-week open-label extension; belimumab patients received the same dose or were switched to 10 mg/kg at the investigator's discretion and former placebo patients received belimumab 10 mg/kg.

03

Conditions studied

  • Lupus Erythematosus, Systemic

Keywords

  • SLE
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Primary Inclusion Criteria

  • Clinical diagnosis of SLE
  • "Active" SLE disease
  • On a stable SLE treatment regimen
  • History of measurable autoantibodies

Primary Exclusion Criteria

  • Received a non-FDA approved agent within last 28 days
  • Cyclosporin, intravenous immunoglobulin (IVIG) or plasmapheresis within last 90 days
  • Active lupus nephritis requiring hemodialysis, cyclophosphamide (Cytoxan™), or high-dose prednisone (> 100 mg/day) within last 90 days
  • Active central nervous system (CNS) lupus requiring therapeutic intervention within last 60 days
  • History of renal transplant
  • History of chronic infection that has been active within last 6 months, herpes zoster within last 90 days or any infection requiring hospitalization or intravenous medication within last 60 days
  • History of hypogammaglobulinemia or immunoglobulin A (IgA) deficiency
  • (HIV), ,
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
449 participants (actual)

Study arms

  • Placebo comparator
    Placebo plus SOC

    Drug: Placebo

  • Experimental
    Belimumab 1 mg/kg plus SOC

    Drug: Belimumab 1 mg/kg

  • Experimental
    Belimumab 4 mg/kg plus SOC

    Drug: Belimumab 4 mg/kg

  • Experimental
    Belimumab 10 mg/kg plus SOC

    Drug: Belimumab 10 mg/kg

Interventions

  • DrugPlacebo

    Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.

  • DrugBelimumab 1 mg/kg

    Drug page: Belimumab

    Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.

    Also known as: LymphoStat-B®, BENLYSTA®

  • DrugBelimumab 4 mg/kg

    Drug page: Belimumab

    Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.

    Also known as: LymphoStat-B®, BENLYSTA®

  • DrugBelimumab 10 mg/kg

    Drug page: Belimumab

    Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on belimumab 10 mg/kg for an additional 24 weeks.

    Also known as: LymphoStat-B®, BENLYSTA®

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24.

    SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare.

    Time frame: Baseline, 24 weeks

  2. Time to First Mild/Moderate or Severe SLE Flare (SLE Flare Index)

    The SLE Flare Index categorized SLE flare as "mild or moderate" or "severe" based on 5 variables: 1) change in SELENA SLEDAI score from the most recent assessment to current, 2) change in signs or symptoms of disease activity, 3) change in prednisone dosage, 4) use of new medications for disease activity or hospitalization, and 5) change in Physician's Global Assessment score, a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe).

    Time frame: 0 to 52 weeks

Secondary outcomes

  1. Percentage Change From Baseline in SELENA SLEDAI Score at Week 52

    SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare

    Time frame: Baseline, 52 weeks

  2. Area Under the Curve (AUC) of SELENA SLEDAI Score at Week 52

    SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare. The normalized AUC was created as the ratio of the area under the SELENA SLEDAI score curve divided by baseline score.

    Time frame: Baseline and every 4 to 8 weeks through Week 52

  3. Percentage Change From Baseline in British Isles Lupus Activity Group (BILAG) Score at Week 52

    The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.

    Time frame: Baseline, 52 weeks

  4. Area Under the Curve (AUC) of BILAG Score at Week 52

    The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.The normalized AUC was created as the ratio of the area under the global BILAG score curve divided by baseline score.

    Time frame: Baseline and every 4 to 8 weeks through Week 52

  5. Time to First Type A/B SLE Flare (as Defined Using BILAG) Over 52 Weeks

    SLE flare indicates an increase in SLE disease activity. An SLE flare was a type A or B SLE flare (as defined using BILAG) compared with the previous visit.

    Time frame: 0 to 52 weeks

  6. Percentage of Patients With a Reduction in Prednisone Dose

    Percentage of patients whose average prednisone dose has been reduced by ≥ 50% and/or has been reduced to ≤ 7.5 mg/day during Weeks 40 through 52 in patients receiving greater than 7.5 mg/day at baseline.

    Time frame: Baseline, weeks 40 to 52

Other outcomes

  1. Adverse Events (AE) Overview

    Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 76/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBSL99/NCT00583362).

    Time frame: Up to 84 weeks

07

Results

Posted Aug 28, 2012

Participant flow

52-Week Double-Blind Period
Participant flow — 52-Week Double-Blind Period
MilestonePlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Started113114111111
Completed93879490
Not completed20271721
Withdrew: Adverse event5848
Withdrew: Lack of efficacy1201
Withdrew: Withdrawal by subject71177
Withdrew: Physician decision1000
Withdrew: Lost to follow-up0022
Withdrew: Pregnancy0100
Withdrew: Protocol violation0110
Withdrew: Death0100
Withdrew: Lack of compliance6333
24-Week Open-Label Extension Period
Participant flow — 24-Week Open-Label Extension Period
MilestonePlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Started01924302
Completed01923279
Not completed00123
Withdrew: Adverse event0016
Withdrew: Lack of efficacy0003
Withdrew: Withdrawal by subject0009
Withdrew: Pregnancy0001
Withdrew: Lost to follow-up0002
Withdrew: Lack of compliance0002

Outcome measures

PrimaryPercentage Change From Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24.

SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare.

Time frame:
Baseline, 24 weeks
Reported as:
Mean · percent change
Percentage Change From Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24.
percent changePlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Percentage Change From Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24.-17.2 ± 5.1-23.3 ± 4.4-11.3 ± 5.4-23.7 ± 4.2
Statistical analysis
  • Placebo Plus SOC vs Belimumab 1 mg/kg Plus SOC · t-test, 2 sided · p = 0.3677 (P-value was not adjusted for multiple testing.) · Mean difference (final values): -6.1 · 95% CI -19.4 to 7.2
  • Placebo Plus SOC vs Belimumab 4 mg/kg Plus SOC · t-test, 2 sided · p = 0.4244 (P-value was not adjusted for multiple testing.) · Mean difference (final values): 5.9 · 95% CI -8.7 to 20.6
  • Placebo Plus SOC vs Belimumab 10 mg/kg Plus SOC · t-test, 2 sided · p = 0.3296 (P-value was not adjusted for multiple testing.) · Mean difference (final values): -6.5 · 95% CI -19.6 to 6.6
PrimaryTime to First Mild/Moderate or Severe SLE Flare (SLE Flare Index)

The SLE Flare Index categorized SLE flare as "mild or moderate" or "severe" based on 5 variables: 1) change in SELENA SLEDAI score from the most recent assessment to current, 2) change in signs or symptoms of disease activity, 3) change in prednisone dosage, 4) use of new medications for disease activity or hospitalization, and 5) change in Physician's Global Assessment score, a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe).

Time frame:
0 to 52 weeks
Reported as:
Median · days
Time to First Mild/Moderate or Severe SLE Flare (SLE Flare Index)
daysPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Time to First Mild/Moderate or Severe SLE Flare (SLE Flare Index)83 (42 to 140)68 (39 to 146)61 (29 to 147)70 (29 to 154)
Statistical analysis
  • Placebo Plus SOC vs Belimumab 1 mg/kg Plus SOC · Log Rank · p = 0.6423 (P-value was not adjusted for multiple testing.)
  • Placebo Plus SOC vs Belimumab 4 mg/kg Plus SOC · Log Rank · p = 0.8536 (P-value was not adjusted for multiple testing.)
  • Placebo Plus SOC vs Belimumab 10 mg/kg Plus SOC · Log Rank · p = 0.9705 (P-value was not adjusted for multiple testing.)
SecondaryPercentage Change From Baseline in SELENA SLEDAI Score at Week 52

SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare

Time frame:
Baseline, 52 weeks
Reported as:
Mean · percent change
Percentage Change From Baseline in SELENA SLEDAI Score at Week 52
percent changePlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Percentage Change From Baseline in SELENA SLEDAI Score at Week 52-20.6 ± 5.2-29.7 ± 4.3-23.9 ± 7.3-27.9 ± 5.5
Statistical analysis
  • Placebo Plus SOC vs Belimumab 1 mg/kg Plus SOC · t-test, 2 sided · p = 0.1763 (P-value was not adjusted for multiple testing.) · Mean difference (final values): -9.1 · 95% CI -22.4 to 4.1
  • Placebo Plus SOC vs Belimumab 4 mg/kg Plus SOC · t-test, 2 sided · p = 0.7112 (P-value was not adjusted for multiple testing.) · Mean difference (final values): -3.3 · 95% CI -20.9 to 14.3
  • Placebo Plus SOC vs Belimumab 10 mg/kg Plus SOC · t-test, 2 sided · p = 0.3320 (P-value was not adjusted for multiple testing.) · Mean difference (final values): -7.4 · 95% CI -22.2 to 7.5
SecondaryArea Under the Curve (AUC) of SELENA SLEDAI Score at Week 52

SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare. The normalized AUC was created as the ratio of the area under the SELENA SLEDAI score curve divided by baseline score.

Time frame:
Baseline and every 4 to 8 weeks through Week 52
Reported as:
Mean · ratio score*days
Area Under the Curve (AUC) of SELENA SLEDAI Score at Week 52
ratio score*daysPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Area Under the Curve (AUC) of SELENA SLEDAI Score at Week 52317.3 ± 14.0288.7 ± 12.5320.3 ± 14.0286.9 ± 13.0
Statistical analysis
  • Placebo Plus SOC vs Belimumab 1 mg/kg Plus SOC · t-test, 2 sided · p = 0.1287 (P-value was not adjusted for multiple testing.) · Mean difference (final values): -28.6 · 95% CI -65.6 to 8.4
  • Placebo Plus SOC vs Belimumab 4 mg/kg Plus SOC · t-test, 2 sided · p = 0.8807 (P-value was not adjusted for multiple testing.) · Mean difference (final values): 2.98 · 95% CI -36.2 to 42.1
  • Placebo Plus SOC vs Belimumab 10 mg/kg Plus SOC · t-test, 2 sided · p = 0.1131 (P-value was not adjusted for multiple testing.) · Mean difference (final values): -30.41 · 95% CI -68.1 to 7.3
SecondaryPercentage Change From Baseline in British Isles Lupus Activity Group (BILAG) Score at Week 52

The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.

Time frame:
Baseline, 52 weeks
Reported as:
Mean · percent change
Percentage Change From Baseline in British Isles Lupus Activity Group (BILAG) Score at Week 52
percent changePlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Percentage Change From Baseline in British Isles Lupus Activity Group (BILAG) Score at Week 52-19.1 ± 4.3-20.8 ± 4.3-26.5 ± 3.4-22.0 ± 4.3
Statistical analysis
  • Placebo Plus SOC vs Belimumab 1 mg/kg Plus SOC · t-test, 2 sided · p = 0.7823 (P-value was not adjusted for multiple testing) · Mean difference (final values): -1.7 · 95% CI -13.8 to 10.4
  • Placebo Plus SOC vs Belimumab 4 mg/kg Plus SOC · t-test, 2 sided · p = 0.1774 (P-value was not adjusted for multiple testing.) · Mean difference (final values): -7.4 · 95% CI -18.2 to 3.4
  • Placebo Plus SOC vs Belimumab 10 mg/kg Plus SOC · t-test, 2 sided · p = 0.6406 · Mean difference (final values): -2.8 · 95% CI -14.8 to 9.1P-value was not adjusted for multiple testing.
SecondaryArea Under the Curve (AUC) of BILAG Score at Week 52

The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.The normalized AUC was created as the ratio of the area under the global BILAG score curve divided by baseline score.

Time frame:
Baseline and every 4 to 8 weeks through Week 52
Reported as:
Mean · ratio score*days
Area Under the Curve (AUC) of BILAG Score at Week 52
ratio score*daysPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Area Under the Curve (AUC) of BILAG Score at Week 52315.4 ± 12.3310.6 ± 12.0300.4 ± 9.3302.7 ± 12.3
Statistical analysis
  • Placebo Plus SOC vs Belimumab 1 mg/kg Plus SOC · t-test, 2 sided · p = 0.7822 (P-value was not adjusted for multiple testing.) · Mean difference (final values): -4.8 · 95% CI -38.6 to 29.1
  • Placebo Plus SOC vs Belimumab 4 mg/kg Plus SOC · t-test, 2 sided · p = 0.3332 (P-value was not adjusted for multiple testing.) · Mean difference (final values): -14.9 · 95% CI -45.3 to 15.4
  • Placebo Plus SOC vs Belimumab 10 mg/kg Plus SOC · t-test, 2 sided · p = 0.4660 (P-value was not adjusted for multiple testing.) · Mean difference (final values): -12.7 · 95% CI -46.9 to 21.5
SecondaryTime to First Type A/B SLE Flare (as Defined Using BILAG) Over 52 Weeks

SLE flare indicates an increase in SLE disease activity. An SLE flare was a type A or B SLE flare (as defined using BILAG) compared with the previous visit.

Time frame:
0 to 52 weeks
Reported as:
Median · days
Time to First Type A/B SLE Flare (as Defined Using BILAG) Over 52 Weeks
daysPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Time to First Type A/B SLE Flare (as Defined Using BILAG) Over 52 Weeks78 (34 to 138)63 (54 to 110)84 (51 to 139)62 (33 to 108)
Statistical analysis
  • Placebo Plus SOC vs Belimumab 1 mg/kg Plus SOC · Log Rank · p = 0.5615 (P-value was not adjusted for multiple comparisons.)
  • Placebo Plus SOC vs Belimumab 4 mg/kg Plus SOC · Log Rank · p = 0.7593 (P-value was not adjusted for multiple testing.)
  • Placebo Plus SOC vs Belimumab 10 mg/kg Plus SOC · Log Rank · p = 0.2273 (P-value was not adjusted for multiple testing.)
SecondaryPercentage of Patients With a Reduction in Prednisone Dose

Percentage of patients whose average prednisone dose has been reduced by ≥ 50% and/or has been reduced to ≤ 7.5 mg/day during Weeks 40 through 52 in patients receiving greater than 7.5 mg/day at baseline.

Time frame:
Baseline, weeks 40 to 52
Reported as:
Number · percentatge of particpants
Percentage of Patients With a Reduction in Prednisone Dose
percentatge of particpantsPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOC
Percentage of Patients With a Reduction in Prednisone Dose27.120.031.444.7
Statistical analysis
  • Placebo Plus SOC vs Belimumab 1 mg/kg Plus SOC · Likelihood ratio chi-squared · p = 0.4355 (P-value was not adjusted for multiple testing.) · Percent difference from placebo: -7.1 · 95% CI -24.7 to 10.6
  • Placebo Plus SOC vs Belimumab 4 mg/kg Plus SOC · Likelihood ratio chi-squared · p = 0.6669 (P-value was not adjusted for multiple testing.) · Percent difference from placebo: 4.4 · 95% CI -15.5 to 24.2
  • Placebo Plus SOC vs Belimumab 10 mg/kg Plus SOC · Likelihood ratio chi-squared · p = 0.0882 (P-value was not adjusted for multiple testing.) · Percent difference from placebo: 17.7 · 95% CI -2.5 to 37.9
Other pre-specifiedAdverse Events (AE) Overview

Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 76/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBSL99/NCT00583362).

Time frame:
Up to 84 weeks
Reported as:
Number · percentage of participants
Adverse Events (AE) Overview
percentage of participantsPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOCOpen-Label Extension Period: All Active
Percent of patients with at least 1 AE97.397.496.497.396.2
Percent of patients with at least 1 SAE19.518.413.516.29.6
Percent of patients with an AE resulting in death00.900.90

Adverse events

Collected over Up to 84 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Plus SOC—22/113 (19.5%)103/113 (91.2%)
Belimumab 1 mg/kg Plus SOC—21/114 (18.4%)107/114 (93.9%)
Belimumab 4 mg/kg Plus SOC—15/111 (13.5%)100/111 (90.1%)
Belimumab 10 mg/kg Plus SOC—18/111 (16.2%)105/111 (94.6%)
Open-label Extension Period: All Active—33/345 (9.6%)312/345 (90.4%)
Most frequent serious events
Showing 10 of 115
Most frequent serious events
EventPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOCOpen-label Extension Period: All Active
PancreatitisGastrointestinal disorders0/1130/1142/1110/1110/345
CholelithiasisHepatobiliary disorders0/1131/1142/1110/1110/345
ProteinuriaRenal and urinary disorders1/1130/1140/1112/1113/345
Non-cardiac chest painGeneral disorders2/1131/1140/1111/1113/345
PleurisyRespiratory, thoracic and mediastinal disorders2/1130/1140/1110/1110/345
CellulitisInfections and infestations0/1132/1141/1110/1111/345
PneumoniaInfections and infestations1/1132/1141/1110/1110/345
Transient ischaemic attackNervous system disorders0/1132/1141/1111/1111/345
Angina pectorisCardiac disorders1/1130/1141/1110/1110/345
Atrial fibrillationCardiac disorders0/1130/1141/1110/1110/345
Most frequent other events
Showing 10 of 72
Most frequent other events
EventPlacebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOCOpen-label Extension Period: All Active
ArthralgiaMusculoskeletal and connective tissue disorders42/11341/11437/11141/111102/345
Upper respiratory tract infectionInfections and infestations33/11336/11436/11129/11158/345
HeadacheNervous system disorders27/11329/11431/11135/11150/345
FatigueGeneral disorders34/11327/11433/11127/11172/345
NauseaGastrointestinal disorders27/11331/11422/11133/11139/345
DiarrhoeaGastrointestinal disorders19/11319/11423/11117/11134/345
ArthritisMusculoskeletal and connective tissue disorders18/11316/11421/11118/11147/345
SinusitisInfections and infestations21/11311/11415/11117/11134/345
Urinary tract infectionInfections and infestations18/11316/11418/11120/11133/345
Oedema peripheralGeneral disorders13/11315/11418/11115/11141/345

Baseline characteristics

Age Continuous
Age Continuous(years)Placebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOCTotal
Mean42.2 ± 10.942.0 ± 11.742.6 ± 10.741.8 ± 11.742.2 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOCTotal
Female102107105105419
Male1176630
Region of Enrollment
Region of Enrollment(participants)Placebo Plus SOCBelimumab 1 mg/kg Plus SOCBelimumab 4 mg/kg Plus SOCBelimumab 10 mg/kg Plus SOCTotal
United States113113111109446
Canada01023
08

Study locations

62 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-0006, United States
  • Arizona Arthritis Research
    Paradise Valley, Arizona 85253, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • Scripps Clinic
    LaJolla, California 92037, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Stanford University School of Medicine
    Palo Alto, California 94304, United States
  • Boling Clinical Trials
    Rancho Cucamonga, California 91730, United States
  • UCDMC
    Sacramento, California 95817-1418, United States
  • Arthritis Care Center, Inc.
    San Jose, California 95126-1650, United States
  • Arthritis Associates & Osteoporosis Center Of Colorado Springs
    Colorado Springs, Colorado 80910, United States
  • Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Arthritis and Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • Rheumatology Associates of Central Florida
    Orlando, Florida 32806, United States
  • Tampa Medical Group, P.A.
    Tampa, Florida 33614, United States
  • Emory University
    Atlanta, Georgia 30303, United States
  • Radiant Research Boise
    Boise, Idaho 83704, United States
  • Institute of Arthritis and Research
    Idaho Falls, Idaho 83404, United States
  • Northwestern University Medical School
    Chicago, Illinois 60611, United States
  • Rheumatology Associates
    Chicago, Illinois 60612, United States
  • Medical Specialists
    Munster, Indiana 46321, United States
  • Kentuckiana Center for Better Bone and Joint Health
    Louisville, Kentucky 40202, United States
  • Ochsner Clinic Foundation
    Baton Rouge, Louisiana 70809, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • The Osteoporosis and Arthritis Clinical Trial Center
    Cumberland, Maryland 21502, United States
  • Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • Tufts--New England Medical Center
    Boston, Massachusetts 02111, United States
  • The University of Michigan Health System
    Ann Arbor, Michigan 48109-0358, United States
  • Washington University in St. Louis
    St. Louis, Missouri 63110, United States
  • Arthritis Center of Nebraska
    Lincoln, Nebraska 68506, United States
  • Arthritis and Osteoporosis Center
    Concord, New Hampshire 03301, United States
  • Strafford Medical Associates, P.A.
    Dover, New Hampshire 03820, United States
  • The Center for Rheumatology
    Albany, New York 12206, United States
  • Jacobi Medical Center
    Bronx, New York 10461, United States
  • SUNY-Downstate Medical Center
    Brooklyn, New York 11203, United States
  • North Shore University Hospital
    Manhasset, New York 11030, United States
  • Aair Research
    Rochester, New York 14618, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599-7280, United States
  • Arthritis Clinic and Carolina Bone and Joint
    Charlotte, North Carolina 28210, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • Stat Research Inc.
    Dayton, Ohio 45402, United States
  • Bone and Joint Hospital
    Oklahoma City, Oklahoma 73103, United States
  • Oklahoma Medical Research Foundation
    Oklahoma City, Oklahoma 73104, United States
  • Oklahoma Center For Arthritis Therapy & Research
    Tulsa, Oklahoma 74114, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • University of Pittsburgh School of Medicine & ASPH
    Pittsburgh, Pennsylvania 15261, United States
  • Rheumatic Disease Associates
    Willow Grove, Pennsylvania 19090, United States
  • Research Associates of North Texas
    Dallas, Texas 75246, United States
  • UT Southwestern Medical Center at Dallas
    Dallas, Texas 75390-8884, United States
  • Texas Research Center
    Sugar Land, Texas 77479, United States
  • Arthritis and Rheumatic Disease Clinic
    Ogden, Utah 84044, United States
  • Physicians Research Options, LC
    Sandy, Utah 84070, United States
  • Arthritis Clinic of Northern Virginia, P.C.
    Arlington, Virginia 22205, United States
  • Edmonds Rheumatology Associates
    Edmonds, Washington 98026-8047, United States
  • Arthritis Northwest Rheumatology
    Spokane, Washington 99204, United States
  • Gundersen Clinic, Ltd.
    La Crosse, Wisconsin 54610, United States
  • The Medical College of Wisconsin , Inc
    Milwaukee, Wisconsin 53226, United States
  • Marshfield Medical Research Foundation
    Wausau, Wisconsin 54401, United States
  • Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
  • McGill University Health Center
    Montreal, Quebec H3G 1A4, Canada
09

References and documents

Publications

  • Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699. PubMed 19714604 ↗
  • Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15;61(9):1143-51. doi: 10.1002/art.24698. PubMed 19714615 ↗
  • Gupta SV, Fanget MC, MacLauchlin C, Clausen VA, Li J, Cloutier D, Shen L, Robbie GJ, Mogalian E. Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection. Drugs R D. 2021 Dec;21(4):455-465. doi: 10.1007/s40268-021-00369-w. Epub 2021 Nov 6. PubMed 34741731 ↗
  • Zhou X, Lee TI, Zhu M, Ma P. Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus. Drugs R D. 2021 Dec;21(4):407-417. doi: 10.1007/s40268-021-00363-2. Epub 2021 Oct 9. PubMed 34628605 ↗
  • Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 2021 Sep;7(3):e001747. doi: 10.1136/rmdopen-2021-001747. PubMed 34531304 ↗
  • Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2. PubMed 33687069 ↗
  • Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1. PubMed 24187095 ↗
  • Struemper H, Chen C, Cai W. Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus. J Clin Pharmacol. 2013 Jul;53(7):711-20. doi: 10.1002/jcph.104. Epub 2013 May 16. PubMed 23681782 ↗
  • Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, Levy RA, van Vollenhoven RF, Cooper S, Zhong ZJ, Freimuth W, Cervera R; BLISS-52 and -76, and LBSL02 Study Groups. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013 Feb;22(2):144-54. doi: 10.1177/0961203312469259. Epub 2012 Dec 4. PubMed 23213069 ↗
  • Merrill JT, Ginzler EM, Wallace DJ, McKay JD, Lisse JR, Aranow C, Wellborne FR, Burnette M, Condemi J, Zhong ZJ, Pineda L, Klein J, Freimuth WW; LBSL02/99 Study Group. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Oct;64(10):3364-73. doi: 10.1002/art.34564. PubMed 22674457 ↗
  • Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, Aranow C, Diamond B, Davidson A. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010 Jan;62(1):201-10. doi: 10.1002/art.27189. PubMed 20039404 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003, a primary completion of Aug 2005 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 7 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2003
First posted
Oct 28, 2003
Start
Oct 2003
Primary completionActual
Aug 2005
CompletionActual
Jun 2006
Results first posted
Aug 28, 2012
Last update
Aug 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00071487
Responsible party
Sponsor
First posted
Oct 28, 2003
Start date
Oct 2003
Primary completion
Aug 2005
Completion
Jun 2006
Results posted
Aug 28, 2012
Last update
Aug 7, 2013

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion